Shi Laboratory

Histone Modifications and Chromatin Regulation

Each year, more than 1.6 million people in the U.S. are diagnosed with cancer. Globally, the number of people with the disease is expected to rise 50 percent in the coming years, jumping from 14 million in 2012 to an estimated 21 million by 2030.

This impending increase reinforces the importance of understanding the complex constellation of factors that contribute to cancer and leveraging this knowledge to find new, improved prevention and treatment methods. To this end, the Shi Laboratory seeks to discern how epigenetics — mechanisms that regulate how DNA is read and acted upon — impact cancer risk, development and progression.

Specifically, the Shi Laboratory investigates a number of posttranslational modifications on histones, which play an important role in modulating chromatin dynamics and the accessibility of the underlying DNA, thus regulating all chromatin-associated processes, such as transcription. Dysregulation of histone modification homeostasis leads to pathogenesis of developmental disorders and genetic diseases, including cancer.

However, despite the clear biological and clinical importance, it remains largely unknown how modifications on the histone tails dictate gene expression profiles. One of the principal functions of histone methylation and acetylation is believed to be to recruit or repel “reader” proteins that recognize the methyl or acetyl moiety on specific residues and transduce the epigenetic signals to distinct outcomes. Therefore, identification of reader proteins is critical for understanding the mechanistic and functional consequences of histone modifications.

The long-term goal of the Shi Laboratory’s research is to understand the molecular mechanisms by which histone modifications, particularly lysine methylation and acetylation, regulate chromatin and transcription and how dysregulation of the homeostasis of histone modifications leads to human cancer. Their current research focus is to identify and characterize novel epigenetic readers and to elucidate their roles in cancer.

Our Impact

We’re raising thousands to save millions.

We’re turning hope into action for the millions of people around the world affected by diseases like cancer and Parkinson’s. Find out how you can help us make a difference.

  • 141 peer-reviewed papers published in 2025, 74 of which were in high-impact journals
  • 15 VAI-SU2C Epigenetics Dream Team clinical trials launched to date
  • 10 clinical trials and related projects supported by VAI through the International Linked Clinical Trials Program

Xiaobing Shi, Ph.D.

Professor, Department of Epigenetics

Areas of Expertise

Chromatin, post-translational modifications, epigenetics, cancer

Biography

Dr. Xiaobing Shi is an expert in cancer epigenetics and a professor in the Department of Epigenetics at Van Andel Institute. He earned a B.S. in biology from Wuhan University followed by a Ph.D. in biology from the Chinese Academy of Sciences, both with honors. He subsequently completed postdoctoral fellowships in the labs of Drs. Arthur Kornberg and Or Gozani at Stanford University before accepting a faculty position at University of Texas MD Anderson Cancer Center, where he most recently served as an Associate Professor and Co-Director of the Center for Cancer Epigenetics. Dr. Shi’s work has led to the discovery of several new readers of histone posttranslational modifications, particularly in acetylation and methylation, and elucidated their impact on cancer development. He is the recipient of several prestigious awards, including a Career Development Award from the Leukemia & Lymphoma Society, a Research Scholar Award from the American Cancer Society, a Kimmel Scholar Award from the Sidney Kimmel Foundation, and an inaugural R. Lee Clark Fellow from UT M.D. Anderson Cancer Center.

Society Memberships

American Society for Biochemistry and Molecular Biology
American Association for Cancer Research
American Association for the Advancement of Science

Publications

# Equal contributions * Co-corresponding authors

Selected Publications Before 2009

# Equal contributions * Co-corresponding authors

Jennifer Brooks

Senior Administrative Assistant I, Department of Epigenetics

Hongkuan Wang, Ph.D.

Research Scientist, Department of Epigenetics

Identifying novel epigenetic readers and their inhibitors